Multidrug resistance: Physiological principles and nanomedical solutions

Area of Science:

• Oncology
• Nanomedicine
• Pharmacology

Background:

• Multidrug resistance (MDR) in cancer cells impedes effective chemotherapy.
• Overexpression of ATP-binding cassette (ABC) transporters like P-glycoprotein (Pgp/ABCB1) and MRP (ABCC1) drives MDR.
• Current chemotherapeutic strategies face limitations due to MDR.

Purpose of the Study:

• To review nanomedical strategies for overcoming MDR in cancer.
• To discuss the physiological basis of MDR and its molecular mechanisms.
• To explore the potential of nanomedicine in treating multidrug-resistant malignancies.

Main Methods:

• Review of existing literature on MDR mechanisms and nanomedicine applications.
• Analysis of strategies involving carrier materials with anti-MDR properties.
• Evaluation of nanomedicines for altering cellular drug uptake.
• Assessment of co-formulation approaches combining drugs with MDR inhibitors.

Main Results:

• Nanomedicine offers diverse strategies to combat MDR, including intrinsic anti-MDR materials and modified cellular uptake.
• Co-formulation of chemotherapeutics with MDR inhibitors in nanodelivery systems shows promise.
• Nanomedical approaches can overcome limitations imposed by drug efflux pumps.

Conclusions:

• Nanomedicine formulations demonstrate significant potential for improving treatment outcomes in multidrug-resistant cancers.
• While clinical translation faces challenges, nanomedicine represents a promising frontier in oncology.
• Further research and development are crucial for widespread clinical application of these nanomedical strategies.